Skip to the content
  • Our Company
    • Management Team
    • Board Members
    • Events
  • Our Approach
  • Partner
  • Careers
  • Resources
  • News
Menu
  • Our Company
    • Management Team
    • Board Members
    • Events
  • Our Approach
  • Partner
  • Careers
  • Resources
  • News
  • Contact
Menu
  • Contact

Nimble Announces Collaboration with Genentech to Discover and Develop Novel Peptide-Based Therapeutics

read more
Path 3
  • Press Release
  • February 19, 2020

Madison, WI, USA, Feb. 19, 2020 — Nimble Therapeutics, Inc. today announced a multi-year collaboration with Genentech, a member of the Roche Group, to accelerate discovery and development of novel peptide-based medicines for targets across a range of diseases.

The collaboration will leverage Nimble’s proprietary peptide synthesis, screening and optimization platform, chemical diversity, and integrated suite of assays to enable faster discovery and optimization of promising compounds for intracellular and extracellular targets.

“We are excited to collaborate with a world class and well-respected organization such as Genentech to identify novel peptide therapeutics,” said Jigar Patel, Ph.D., Chief Executive Officer of Nimble Therapeutics. “This partnership combines the strengths of our two organizations to potentially bring new medicines to patients.”

Under the terms of the agreement, Nimble will receive an undisclosed upfront payment and will be eligible for downstream milestone payments and royalties.

PreviousIdentification of immunoreactive linear epitopes of Borrelia miyamotoi.
NextMicroarray analyses reveal strain-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 variants following natural infection and vaccination.
PreviousIdentification of immunoreactive linear epitopes of Borrelia miyamotoi.
NextMicroarray analyses reveal strain-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 variants following natural infection and vaccination.
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact

603 Science Dr
Madison, WI, USA 53711

LinkedIn
  • Nimble Therapeutics Announces Expansion of its Discovery and Development Partnership with Genentech
    Read More